Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares of oncology drug development consultancy Physiomics (LON: PYC) are rallying on Friday after the company revealed it has been awarded a further contract by existing client Merck KGaA.
The company expects to complete the contract over the next two to three months. It is a follow-on and adds to the initial tranche of projects with Merck announced on the 17th of December 2020, with a value of £270k, intended to be completed in the first six to eight months of 2021.
Since 2019, Merck has awarded contracts to Physiomics in November or December to cover the first two to three quarters of the following calendar year and then extended these or awarded new contracts during the year.
Today's contract announcement by Physiomics represents the first extension, and the AIM company stated that others will be announced as and when they are agreed.
Physiomics share price jumped over 10% at the open on Friday. It is currently priced at 6.58p, up 9.65% from Thursday's close. However, for the year to date, the AIM stocks share price is down 10.49%.
Physiomics shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Physiomics shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .